# ALEX (NCT02075840)

> A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02075840
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Alectinib; Crizotinib
- Enrollment: 303
- Primary outcome: Progression-Free Survival (PFS) by Investigator Assessment
- Primary outcome: Percentage of Participants With PFS Event by Investigator Assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 27
- Podcasts: 23
- YouTube: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=alex-nct02075840

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02075840", "email": "<work email>"}; the inbox owner confirms by the emailed link.